Spravato savings card: as little as $10 a treatment with commercial insurance

How to pay the least

Ask for the cash price

Spravato

No generic is sold yet.

Ask your pharmacy for Spravato’s cash price, and one or two other pharmacies too.
Spravato’s savings card works only with insurance from a job or one you bought.

Free from the maker, if you qualify Johnson & Johnson Patient Assistance Program. Patients’ income must be equal to or less than 300% of Federal Poverty Level (FPL). Or call 1-833-742-0791.

See if you qualify

Compare every option

Brand nameSpravato

Authorized genericesketamine

Regular genericesketamine

What you’d pay

Cash priceAsk the pharmacy

Not soldThere isn’t one

Not soldNone sold yet

Same as Spravato?

The original

–

Brand nameThe maker’s card

SPRAVATO withMe Savings Program

Savings card from Johnson & Johnson (Janssen)

No insuranceNeeds insuranceNo cash price listed.

Insurance · as little as $10 a treatment

Or call 1-844-479-4846.

In the maker’s words

“Eligible patients pay $10 per treatment for SPRAVATO medicine costs…”

From the maker’s offer on jnjwithme.com, checked November 2, 2026. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.

Maker’s card or discount card?

A discount card like GoodRx lowers the pharmacy’s cash price, but for a brand-name drug that price often stays high. Compare it with the maker’s card above. You can usually use one or the other on a fill, not both.

Authorized genericNot sold

There isn’t one. An authorized generic is Spravato itself, from the same company, sold without the brand name, and usually for less. For now Spravato is the only choice; its maker’s savings card can lower what you pay.

See the brand name →

Regular genericNot sold

No generic is sold yet. Generics usually come once the brand’s patents and exclusivity end. Until then, the maker’s savings card is the way to pay less.

See the brand name →

What it’s used for

What the FDA label says

SPRAVATO is a non-competitive N-methyl D-aspartate (NMDA) receptor antagonist indicated for the treatment of:

Treatment-resistant depression (TRD) in adults, as monotherapy or in conjunction with an oral antidepressant.
Depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior in conjunction with an oral antidepressant.

Limitations of Use:

The effectiveness of SPRAVATO in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO.
SPRAVATO is not approved as an anesthetic agent. The safety and effectiveness of SPRAVATO as an anesthetic agent have not been established.

Source: the FDA label for Spravato (Janssen Pharmaceuticals, Inc.), September 22, 2026. Full label on DailyMed

Good to know

“Commercial insurance” means a plan from a job, from the marketplace, or one you buy yourself. A retiree plan that’s part of Medicare counts as Medicare. Co-pay cards can’t be used with Medicare (including Medicare Advantage), Medicaid, TRICARE or VA.
Most cards need a sign-up on the maker’s site, and many work only if your plan covers the drug. Then give the card’s details to your pharmacy.
Don’t stop or change a medicine without talking to your pharmacist or prescriber.

Prices checked November 2, 2026. Prices change: confirm with the pharmacy before you fill. drugalt.com/drug/spravato/